PRE vs. CERO, FHLT, ARYD, FEMY, MRM, LEXX, NMTC, EVGN, PLUR, and OMIC
Should you be buying Prenetics Global stock or one of its competitors? The main competitors of Prenetics Global include CERo Therapeutics (CERO), Future Health ESG (FHLT), ARYA Sciences Acquisition Corp IV (ARYD), Femasys (FEMY), MEDIROM Healthcare Technologies (MRM), Lexaria Bioscience (LEXX), NeuroOne Medical Technologies (NMTC), Evogene (EVGN), Pluri (PLUR), and Singular Genomics Systems (OMIC). These companies are all part of the "medical" sector.
Prenetics Global (NASDAQ:PRE) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 84.8% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 81.09%. Given Prenetics Global's higher probable upside, research analysts plainly believe Prenetics Global is more favorable than CERo Therapeutics.
Prenetics Global received 5 more outperform votes than CERo Therapeutics when rated by MarketBeat users.
CERo Therapeutics has a net margin of 0.00% compared to Prenetics Global's net margin of -193.60%. CERo Therapeutics' return on equity of 0.00% beat Prenetics Global's return on equity.
CERo Therapeutics has lower revenue, but higher earnings than Prenetics Global.
Prenetics Global has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500.
In the previous week, Prenetics Global had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for Prenetics Global and 1 mentions for CERo Therapeutics. Prenetics Global's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.
Summary
Prenetics Global beats CERo Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Prenetics Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prenetics Global Competitors List
Related Companies and Tools
